[LCID Study Number: 2017-085CIRB]
S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
The purpose of this study is to compare any good and bad effects of using a combination of antibodies, trastuzumab and pertuzumab, to using the usual chemotherapy, cetuximab and irinotecan, in patients with advanced colorectal cancer that cannot be removed by surgery.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3055